Overview

A Study for GSK3862995B in Healthy Participants and Participants With Chronic Obstructive Pulmonary Disease

Status:
Not yet recruiting
Trial end date:
2026-03-13
Target enrollment:
Participant gender:
Summary
The primary objective of the study is to investigate the safety and tolerability of ascending doses of GSK3862995B following single dose in healthy participants and repeat doses in participants with Chronic obstructive pulmonary disease (COPD).
Phase:
Phase 1
Details
Lead Sponsor:
GlaxoSmithKline